The leading pharmaceutical manufacturer in Ukraine*, Farmak, launched 22 new products in 2024. Among them are prescription and over-the-counter drugs, medicinal products and dietary supplements.
The new products are designed to maintain fluid balance during operations; for muscle relaxation during surgical interventions; treatment of wounds, bedsores, frostbite; an infusion antibiotic indicated for community-acquired pneumonia; a drug for lowering blood pressure; an analgesic drug; for the treatment of angina, etc.
The medicines that have expanded the Farmak portfolio are produced in various forms to ensure maximum convenience for patients and healthcare professionals. Among them are products in the form of a spray, gel, solutions, tablets.
Today, Farmak’s product portfolio includes more than 450 names of medicines, covering almost all therapeutic areas, including endocrinology, cardiology, gastroenterology, neurology, gynecology, ophthalmology, etc.
Thanks to high production quality standards and compliance with European GMP (good manufacturing practice) requirements, the company’s products are exported to more than 60 countries, including Denmark, Israel, Hong Kong, UAE, Poland, Slovakia, Czech Republic, Mexico. In 2024, Farmak’s export geography expanded by entering the markets of Jordan and Pakistan.
In addition, last year the company registered a general anesthesia drug in the UK and a contrast agent for magnetic resonance therapy in China, which confirms the recognition of Farmak products in markets with high regulatory requirements and strong competition.
* In terms of sales volumes of medicines in monetary terms, according to Proxima Research, for 9 months. 2024
